28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: A randomized placebo-controlled trial

Pulmonary Pharmacology and Therapeutics

Volumn 25, Issue 6, 2012, Pages 465-471

  Feldman, Gregory ^a   Walker, Robert R ^b   Brooks, Jean ^c   Mehta, Rashmi ^d   Crater, Glenn ^d  

^a S Carolina Pharmaceutical Research   (United States)

^b Greenville Pharmaceutical Research   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

Author keywords

COPD; GSK573719; LABA; LAMA; Umeclidinium; Vilanterol

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; PLACEBO; SALBUTAMOL; THEOPHYLLINE; UMECLIDINIUM; VILANTEROL;

ABNORMAL DREAMING; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PLEURISY; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SMOKING; SPIROMETRY; SYSTOLIC BLOOD PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; TONGUE SWELLING; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BENZYL ALCOHOLS; CHLOROBENZENES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINUCLIDINES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84870236438     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2012.08.007     Document Type: Article

References (17)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Guidelines on COPD diagnosis, prevention and management (Revised 2011). Available from: Last accessed 21 June 2012. http://www.goldcopd.org/.
2. Mahler D.A., D'Urzo A., Peckitt C., Lassen C., Kramer B., Filcek S. Combining once-daily bronchodilators in COPD: indacaterol plus tiotropium versus tiotropium alone [abstract]. Am J Respir Crit Care Med 2011, 183:A1591.
3. Spiriva (tiotropium) prescribing information. Available from: Last accessed 21 June 2012. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser%3FdocBase%3Drenetnt%26FolderPath%3D/Prescribing+Information/PIs/Spiriva/Spiriva.pdf.
4. Serevent (salmeterol) prescribing information. Available from:: Last accessed 21 June 2012. http://us.gsk.com/products/assets/us_serevent_diskus.pdf.
5. Arcapta (indacaterol) prescribing information. Available from: Last accessed 21 June 2012. http://www.pharma.us.novartis.com/product/pi/pdf/arcapta.pdf.
6. Kempsford R.D., Norris V., Siederer S.K. GW642444, a novel inhaled long-acting beta2 adrenoceptor agonist (LABA), at single doses of 25, 50 and 100 mcg, is well tolerated and demonstrates prolonged bronchodilation in COPD subjects [abstract]. Am J Respir Crit Care Med 2010, 181:A4447.
7. Hanania N.A., Feldman G., Zachgo W., Shim J.J., Crim C., Sanford L., et al. The efficacy and safety of the novel long-acting β2 agonist vilanterol in COPD patients: a randomized placebo-controlled trial. Chest 2012, 142:119-127.
8. Mehta R., Hardes K., Cahn A., Newlands A., Donald A., Preece A., et al. Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults [abstract]. Eur Resp J 2011, 38(Suppl. 5):723s.
9. Kelleher D., Preece A., Mehta R., Donald A., Hardes K., Cahn A., et al. Phase II study of once-daily GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD) [abstract]. Eur Resp J 2011, 38(Suppl. 55):140s.
10. Donohue J.F., Anzueto A., Brooks J., Mehta R., Kalberg C., Crater G. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med 2012, 106:970-979.
11. Feldman G., Walker R.R., Brooks J., Mehta R., Crater G. Safety and tolerability of the GSK573719/vilanterol combination in patients with COPD [abstract]. Am J Respir Crit Care Med 2012, 185:A2938. Meeting Abstracts.
12. Celli B.R., MacNee W. Standards of the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23:932-946.
13. Hankinson J.L., Odencrantz J.R., Fredan K.B. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med 1999, 159:179-187.
14. World Medical Associate Declaration of Helsinki - ethical principles for medical research involving human subjects 1964, and updates to 2008.
15. Kempsford R.D., Norris V., Siederer S.K. The pharmacodynamics, pharmacokinetics and tolerability of repeat doses of the novel inhaled long-acting beta2 adrenoceptor agonist (LABA) GW642444 (25, 50 and 100mcg) in healthy subjects [abstract]. Am J Respir Crit Care Med 2010, 181:A4461.
16. Mehta R., Newlands A., Kelleher D., Preece A., Cahn A., Crater G. Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 Inhalation Powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPD [abstract]. Eur Resp J 2011, 38(Suppl. 55):138s.
17. Cahn A., Lovick R., Newlands A., Deans A., Pouliquen I., Preece A., et al. Safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of GSK573719 inhalation powder in healthy subjects [abstract]. Eur Resp J 2011, 38(Suppl. 55):723s.